高效液相色谱法测定血浆中替考拉宁的血药浓度

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (610 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To establish a method for detecting Teicoplanin plasma concentrations. Methods Plasma samples were pretreated by acetonitrile precipitation of protein and dichloromethane extraction, and Piperacillin sodium was used as internal standard. Diamonsil C18 chromatographic column (4.6 mm × 150 mm, 5 μm) was used as chromatographic column, acetonitrile and 0.01 mol/L potassium dihydrogen phosphate solution (25∶75) (adjust pH value to 2.8 with phosphoric acid solution) was used as mobile phase, the column temperature was 30℃, the flow rate was 1.2 ml/min, the detection wavelength was 215 nm, the injection volume was 20 μl. Results The peaks of Teicoplanin and internal standard were well shaped with retention times of about 7.3 min and 12.5 min, respectively. Linear regression equation was Y=11.295 386X-0.048 985 (r=0.9987), linear range was 3.125 to 100.000 μg/ml. The intra batch and inter batch accuracy were in the range of 85% to 115%. The relative standard deviation within and between batches was less than 15%. The recoveries of Teicoplanin and internal standard were in the range of 85% to 115%. Conclusion The plasma concentration of Teicoplanin can be determined by high performance liquid chromatography. The method is simple, feasible, specific and reproducible. Methodological indicators are in line with the requirements of Pharmacopoeia of the People′s Republic of China.

Key words： High performance liquid chromatography Teicoplanin Piperacillin sodium Blood drug concentration Therapeutic drug monitoring

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Qin
	YAO Yan

Cite this article:

WANG Qin,YAO Yan. Determination of Teicoplanin in plasma by high performance liquid chromatography[J]. 中国当代医药, 2022, 29(20): 10-13.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I20/10

[13]	郑灵招，林小青，温悦，等.影响替考拉宁谷浓度的多因素分析及预测模型研究[J].临床药物治疗杂志，2021，19（7）：15-20.
[1]	Yushchuk O，Ostash B，Truman AW，et al.Teicoplanin biosynthesis：unraveling the interplay of structural，regulatory，and resistance genes[J].Appl Microbiol Biotechnol，2020，104（8）：3279-3291.
[2]	Destrem AL，Valour F，Ronde-Ousteau C，et al.Subcutaneous teicoplanin in staphylococcal bone and joint infections[J].Med Mal Infect，2020，50（1）：83-86.
[3]	Ramos-Martín V，Johnson A，McEntee L，et al.Pharmacodynamics of teicoplanin against MRSA[J].J Antimicrob Chemother，2017，72（12）：3382-3389.
[4]	何丹，董娜，朱怀军，等.基于替考拉宁群体药物代谢动力学模型的个体化给药研究进展[J].临床药物治疗杂志，2020，18（5）：38-42.
[5]	Lim SK，Lee SA，Kim CW，et al.High variability of teicoplanin concentration in patients with continuous venovenous hemodiafiltration[J].Hemodial Int，2019，23（1）：69-76.
[6]	刘莹，简凤壁，梁桐，等.重症感染患者替考拉宁血药浓度影响因素探讨[J].中国抗生素杂志，2021，46（10）：964-969.
[7]	Tengattini S，Corana F，Bianchi D，et al.Application of an HPLC-MS/MS method for Teicoplanin drug substance and related impurities，part 2：Identity assignment of related impurities[J].J Pharm Biomed Anal，2019，168（5）：38-43.
[8]	Papp LA，Foroughbakhshfasaei M，Fiser B，et al.Reversed-phase HPLC enantioseparation of pantoprazole using a teicoplanin aglycone stationary phase-Determination of the enantiomer elution order using HPLC-CD analyses[J].Chirality，2020，32（2）：158-167.
[9]	胡雪莹，李坦，昂韦，等.替考拉宁在感染的血液病患者中血药浓度的监测与应用价值分析[J].现代生物医学进展，2021，21（1）：188-192.
[10]	陈悦，汪素岩，胡功允.微生物检定法测定替考拉宁及注射用替考拉宁的含量[J].中国药学杂志，2002，37（4）：302-304.
[11]	王曦培，何国东，郑志杰，等.高效液相色谱-质谱联用法检测患者血浆中替考拉宁的浓度[J].中国医院药学杂志，2020，40（15）：1616-1621.
[12]	邹舒鹏，何正，黄镇，等.HPLC法测定患者血浆中替考拉宁浓度及临床实践[J].中国药师，2021，24（3）：596-599.
[14]	Li H，Gao L，Zhou L，Wang Y，et al.Optimal teicoplanin loading regimen to rapidly achieve target trough plasma concentration in critically ill patients[J].Basic Clin Pharmacol Toxicol，2020，126（3）：277-288.
[15]	国家药典委员会.中华人民共和国药典（2020年版）[S].四部.北京：中国医药科技出版社，2020：61-65.
[16]	任小强，唐莲，许晓文，等.替考拉宁用于危重症感染患者治疗的血药浓度监测及临床疗效分析[J].中国急救医学，2021，41（8）：688-692.
[17]	陈明，唐原君，王倩茹，等.基于质控图联合Westgard多规则理论的替考拉宁血药浓度监测的室内质控评估[J].实用药物与临床，2021，24（10）：933-937.
[18]	Wang XX，Jin PF，Li PM，et al.Interlaboratory analysis of teicoplanin plasma concentration assays among Chinese laboratories[J].J Clin Pharm Ther，2020，45（5）：983-990.
[19]	Sato Y，Hiramatsu K，Suzuki Y，et al.Optimal Trough Concentration of Teicoplanin in Febrile Neutropenic Patients with Hematological Malignancy[J].Chemotherapy，2018，63（1）：29-34.
[20]	王娜，周丽娟，张华，等.药代动力学指导下应用替考拉宁治疗重症革兰阳性球菌感染[J].中华医院感染学杂志，2021，31（7）：1006-1010.
[21]	秦又发，朱永坤，卢浩杨，等.高效液相色谱法测定人血清中替考拉宁浓度的不确定度评定[J].中国医院药学杂志，2019，39（15）：1526-1531.